Intranasal insulin could benefit patients with Alzheimer's, MCI

07/20/2010 | Medscape (free registration)

A trial involving patients with mild cognitive impairment and Alzheimer's disease showed that administering intranasal insulin for four months improved memory and cognitive function, as well as cerebrospinal fluid biomarker profiles, among the patients. FDG-PET imaging also showed that glucose metabolism was intact in areas affected by Alzheimer's pathology in those who received insulin.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Sr Manager, Business Conduct
Gilead Sciences
Foster City, CA
Chief Executive Officer
UCare Minnesota
Minneapolis, MN